Novo Nordisk announced that the Food and Drug Administration (FDA) has approved FlexPro PenMate, which is intended for patients who use Norditropin (somatropin [rDNA origin]) FlexPro 5 mg, 10 mg and 15 mg pens and prefer hidden needles during their injection.
The PenMate consists of a cylindrical attachment that conceals the needle so patients cannot see it being injected into their skin. The Norditropin FlexPro pen twists into the FlexPro PenMate and is locked in. The needle then gets attached and the injection can begin. The PenMate also has a large gripping surface to allow for a firm hold during injection.
Norditropin FlexPro is a recombinant growth hormone (GH) indicated for growth failure in children due to inadequate endogenous GH secretion, children with short stature associated with Noonan or Turner syndrome, children with short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years and for adults with childhood-onset or adult-onset GH deficiency.
The FlexPro PenMate is designed for use only with the Norditropin FlexPro 5mg, 10mg, and 15mg pens. Novo Nordisk anticipates the launch of FlexPro PenMate in the latter half of this year.
For more information call (888) 668-6444 or visit Norditropin.com.
This article originally appeared on MPR